

## DAFTAR PUSTAKA

1. Ozougwu, J. C.1, Obimba, K. C.2, Belonwu, C. D.3, and Unakalamba, C. B. *The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathofisiology.* 2013 Sep 4 (4): 46-57.
2. American Diabetes Association. *Diagnosis and classification of diabetes mellitus.* Diab Care; 2013: S67-74.
3. Hyun Soon Lee. *Mechanisms and Consequences of TGF- $\beta$  Overexpression by Podocytes in Progressive Podocyte Disease.* 2012; 347(1): 129–140.
4. Francisco J. López-Hernández & Jose M. López-Novoa. *Role of TGF- $\beta$  in chronic kidney disease: an integration of tubular, glomerular and vascular effects.* Cell Tissue Res (2012) 347:141–154
5. Ziyadeh FN. *Mediators of diabetic renal disease: the case for TGF-Beta as the major mediator.* J Am Soc Nephrol 2004;15: S55-7
6. Lee HS, Song CY. *Differential role of mesangial cells and podocytes in TGF-beta-induced mesangial matrix synthesis in chronic glomerular disease.* 2009 Jul;24(7):901-8.
7. A. Iswara. *Efek Pemberian Morinda citrifolia Pada Ginjal Diabetes Nefropaty Tikus Sprague Dawley Diabetes Diinduksi STZ; Dengan Kajian Kadar Albumin Urin, TGF- $\beta$  serum dan Ekspresi Kolagen.* 2011. Tesis Biomedik Undip.
8. Lee Wei Har, Intan safinar Ismail. *Antioksidant Activity Total Phenolics and Total flavonoids of Syzygium polyanthum (Wight) Walp Leaves.* June 2012; 2(2): 219-288.
9. Djoko Wahyono, Susanti *Aktivitas Hipoglikemik Ekstrak Etanolik Daun Salam (Syzygium polyanthum (Wight) Walp) Dan Pengaruhnya Terhadap Stimulasi Parasimpatik Pada Kelinci Jantan Yang Dibebani Glukosa.*
10. Widharna RM, Ferawati, Herdiati L, Surjadhana A, Jonosewojo A, Widjajakusuma EC. *Antidiabetic Properties of Andrographis peniculata Nees and Eugenia polyantha Wight Leaves in Wistar Rats by Oral Glucose Tolerance Test.* Jurnal Tumbuhan Obat Indonesia. Des 2010; 3 (2).
11. Lelono, RAA; Tachibana, Sanro. *Preliminary Studies of Indonesian Eugenia polyantha Leaf Extracts as Inhibitors of Key Enzymes for Type 2 Diabetes.* Journal of Medical Sciences 13.2 (2013): 103-110

12. Perumal S, Mahmud R, Piaru SP, et al. *Potential antiradical activity and cytotoxicity assessment of Ziziphus mauritiana and Syzygium polyanthum*. Int J of Pharm. 2012;8(6): 534-41.
13. Szkudelski T, *The Mechanism of Alloxan and Streptozotocin Action in  $\beta$ -Cell of the Rat Pancreas*, Physiological Research, 2001; (50) 536-546
14. Partini Pudjiastuti Trihono. *Peran Transforming Growth Factor- $\beta$ 1 Terhadap Penyakit Ginjal*. Sari Pediatri, Juni 2011; (13): 1
15. Tisna Tyasasmaya, Dhirgo Adji. *Peranan Transforming Growth Factor  $\beta$ -1 (TGF  $\beta$ -1) dalam Perkembangan Penyakit Jantung Akibat Induksi Diet Lemak Tinggi*. Jurnal Sains Veteriner. Juli 2012; 30 (1): 0126 – 0421.
16. Hyun Soon Lee. *Pathogenic Role of TGF- $\beta$  in Diabetic Nephropathy*. *Diabetes & Metabolism*. Lee. 2013; S9
17. Paine. SK, Basu A, Mondal LK, Sen A, Choudhuri S, Chowdhury IH, Saha A, Bhadhuri G, Mukherjee A, Bhattacharya B. *Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes*. 2012; (18): 2749-2757.
18. M. Bîcu, M. Moța, M. Panduru, C. Grăunțeanu, E. Moța. *Oxidative stress in diabetic kidney disease.rom*. 2010; 48 (4) 307–312
19. P.Zhang, Y.Cai, A.Soofi, and G.R. Dressler. *Activation Of Wnt11 by Transforming Growth Factor- $\beta$  Drives Mesenchymal Gene Expression Through Non-Cononical wnt Protein Signaling In Renal Epithelial Cells*. 2012; 287(25): 21290–21302.
20. Yogesh M. S, Umesh S. D, Harini B. *Mesangial Pathology in Glomerular Disease. Targets for therapeutic intervention*. 2010; 1337-1343.
21. A.Ghayur and Peter J. Margetts. *Transforming growth factor-beta and the glomerular filtration barrier* *Kidney Res Clin Pract*. 2013 March 1; 32(1): 3-10.

22. K.B Gomes, K.F Rodrigues, and A.P Fernandes. *The Role of Transforming Growth Factor-Beta in Diabetic Nephropathy*. Journal of Medical Genetics Volume 2014 (2014), Article ID 180270.
23. H.Ibrahim, A.Hanim Bt Ismail, SB.Ismail, WM.Wan Bebakar. *The use of HbA1C in the diagnosis of diabetes mellitus type 2 in high risk subjects*. Int J Diabetes & Metab (2010) 18:25-28
24. WHO. *Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus*. Abbreviated Report of a WHO Consultation. 2011.
25. CM. Sultanpur, Deepa K & SV. Kumar. *comprehensive review on HbA1c in diagnosis of diabetes mellitus*. July 2010; 3 (2): 0976 – 044
26. J.Prins, BB Van der meijden, EAW.Blokland, JPM.Wielders and RJ.Kraaijenhagen. *Hemoglobin disorders detected in diabetic patients by HbA1c analysis*. Ned Tijdschr Klin Chem Labgeneesk 2005; (30): 4
27. RD.Mahajan, B.Mishra. *Using Glycated Hemoglobin HbA1c for diagnosis of Diabetes mellitus: An Indian perspective*. Int J Biol Med Res. 2011; 2(2): 508-512
28. Brownlee M. Banting Lecture 2004. *The Pathobiology Of Diabetic Complications. A Unifying Mechanism Diabetes*. 2005;54;1615-35.
29. C.Campos, MD, MPH,CDE. *Chronic Hyperglycemia and Glucose Toxicity: Pathology and Clinical Sequelae*. November 2012; 124(6): 0032-5481, e-1941-9260
30. V. Sharma and Sharma PL. Diabetes and Metabolism. *Role of Different Molecular Pathways in the Development of Diabetes-Induced Nephropathy*. J Diabetes Metab 2013, (9)
31. Vilsu P. Patel, V. Lambole, B. N. Shah, P. Shah and Dhiren P. Shah. *A Review On Oxidative Stress And Diabetic Complications*. 1 Apr-Jul 2013; 4 (3): 0976-7908
32. S. de M. Bandeira, L.José S. da Fonseca, Glaucivane da S. G. Luíza A. Rabelo, Marília O. F. Goulart, and SML. Vasconcelos. *Oxidative Stress as an*

*Underlying Contributor in the Development of Chronic Complications in Diabetes Mellitus.*

33. H. Kobori, M. Nangaku, G. Navar, and A. Nishiyama. *The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney Disease*. Pharmacol Rev. 2007 September; 59(3): 251–287
34. Depkes RI. *Materia Medika Indonesia*. Jakarta : Depkes RI, 1980.
35. Murhadi, Suharyono AS, Susilawati. Aktivitas antibakteri ekstrak daun salam (*Syzygium polyantha*) dan daun pandan (*pandanus amaryllifollus*). 2007; 18:(1)
36. A.Sumono, A.Wulan SD. The Use of Bay Leaf (*Eugenia polyantha* Wight) in Density. *Majalah Kedokteran Gigi*. July-September 2008; 41(3)
37. Mun'im A, Hanani E. *Fisioterapi Dasar*. Jakarta: Dian Rakyat.
38. Yohana ANA. *Khasiat Tanaman Obat*. Jakarta : Pustaka Buku Murah, 2008.
39. Herra Studiwan dan Mulja Hadi Santosa. Uji Aktivitas Penurun Kadar Glukosa Darah Ekstrak Daun *Eugenia polyantha* pada Mencit yang Diinduksi Aloksan. *Media Kedokteran Hewan*. Mei 2005; 21(2) .
40. Melhelm MF, Craven PA, Liachenko J and Derubertis FR.  *$\alpha$ -Lipoic Acid Attenuates Hyperglycemia and Prevents Glomerular Mesangial Matrix Expansion in Diabetes*. 2002; 13: 108-16.
41. Makhyan Jibril Al-Farabi. Antibodi terhadap *Advanced Glycation End Product*, Cara Mutakhir Pencegahan Komplikasi Diabetes Melitus. *CDK-210*. 2013; 40(11).
42. Kusuma IW, Kuspradi H, Arung ET, et al. *Biological activity and phytochemical analysis of three Indonesian medical plants, *Murraya koenigii*, *Syzygium polyanthum* and *Zingiber purpurae**. Elsevier. 2011 Jan;4(1) : 75–79.
43. Rini Handayani, Joko Sulisty. 2008. *Sintesis senyawa flavonoid- $\alpha$ -glikosida secara reaksi transglukosilasi enzimatis dan aktivitasnya sebagai antioksidan*. **Biodiversitas**. Januari 2008; 9 (1412-033) 1: 1-4.
44. A.Redha. Flavonoid : *struktur, Sifat Antioksidan dan peranannya dalam sistem biologis*. Sep. 2010; 9 (2): 196-202

45. Ratna Handayani, L. B. S Kardono, Jovita Merilla Wulansari. *Aktivitas antihiperглиkemia pada functional drink daun salam (eugenia polyantha) sebagai inhibitor enzim  $\alpha$ -glukosidase*. Oktober 2006; 4 (2): 1-4
46. Wahyu W, Ratu S, Rymond R, Marlinda S. *Penapisan Aktivitas Superoksida Dismutase pada Berbagai Tanaman*. Juli 2005; 5(1): 2-15.
47. Vienna Saraswaty. *Alpha Glucosidase Inhibitory Activity From Syzigium sp. Teknologi Indonesia* 2010; 33(1): 33–37.
48. Alejandro D. Bolzán, Martha S. Bianchi. *Genotoxicity of Streptozotocin. Mutation Research* .2002. (512) 121–134
49. N.Sakata, G.Yoshimatsu, H.Tsuchiya, S.Egawa, and M.Unno. *Review Article Animal Models of Diabetes Mellitus for Islet Transplantation*. 12 December 2012;
50. J.G. Mabley, Wilma L.S.Pinzon, G.R. Hasko, Andrew L. Salzman, A. Rabinovitch, E.Kun & C.Szabo. *Inhibition of poly (ADP-ribose) synthetase by gene disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone protects mice from multiple-low-dose streptozotocin-induced diabetes*. 2001 133: 909 – 919
51. Melanie L Graham, Jody L Janecek, Jessica A Kittredge, Bernhard J Hering, and Henk-Jan Schuurman. *The Streptozotocin-Induced Diabetic Nude Mouse Model: Differences between Animals from Different Sources*. August 2011; 61(4): 356–360
52. Akbarzadeh A, Norouzian D, Mehrabi MR, Jamshidi S, Farhangi A, Allah A, Mofidian S, Lame Rad B. *Induction of diabetes by streptozotocin in rats*. 2007; 22: 60-64
53. Sastroasmoro S dan Ismail. *Dasar-dasar metodologi penelitian klinis*. Edisi 3. Jakarta : Sagung Seto, 2008 : 93-111.
54. Cha DR, Kang YS, Sang Youb Han YHJea. *Vascular Endothelial Growth Factor is Increased During Early Stage of Diabetic Nephropaty in Tipe II Diabetic Rats*. 2004; 81-84
55. Arora S, Ojha SK, Vohora D. *Characterisation of Streptozotocin Induced Diabetes Melitus in Swiss Albino Mice*. 2009; 3(2): 81-4.

56. Nakagawa, T., Kosugi, T., Haneda, M., Rivard, C. J. & Long, D. A., Abnormal Angiogenesis in Diabetic Nephropathy. *Diabetes Journal* **58**, 1471-1478 (2009).